Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia

Christian Kellner; Matthias Peipp; Martin Gramatzki; Martin Schrappe; Denis M Schewe

doi:10.1080/2162402X.2018.1448331

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia

Oncoimmunology. 2018 Apr 9;7(8):e1448331. doi: 10.1080/2162402X.2018.1448331. eCollection 2018.

Authors

Christian Kellner¹, Matthias Peipp¹, Martin Gramatzki¹, Martin Schrappe², Denis M Schewe²

Affiliations

¹ Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
² Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany.

Abstract

CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential. In light of recent preclinical and clinical data, perspectives of such antibodies designed for improved effectiveness in BCP-ALL are presented.

Keywords: Acute lymphoblastic leukemia; CAR T cells; CD19; Fc engineering; bispecific antibodies.

Publication types

Research Support, Non-U.S. Gov't